Table 8.

Use of FFP and other blood components



OLT patients; n = 51

Non-OLT patients; n = 70

PCT-FFP (no.)
C-FFP (no.)
PCT-FFP (no.)
C-FFP (no.)
Units of study FFP*  21.3 ± 16.1 (22)   22.7 ± 15.8 (29)   7.2 ± 7.9 (38)   9.6 ± 12.9 (32)  
Volume of study FFP, L  4.8 ± 3.7   5.2 ± 3.6   1.6 ± 1.7   2.2 ± 3.0  
Off-study FFP  0.5 ± 1.9 (2)   0.7 ± 2.4 (4)   0.1 ± 0.3 (1)   0.6 ± 2.1 (3)  
Red blood cells§  11.8 ± 6.1 (22)   13.4 ± 10.2 (29)   3.8 ± 2.2 (21)   4.9 ± 4.9 (16)  
Platelets§  13.4 ± 11.3 (18)   16.5 ± 17.3 (24)   7.6 ± 17.0 (16)   6.1 ± 7.2 (9)  
Cryoprecipitate
 
15.8 ± 8.4 (9)
 
13.8 ± 5.2 (8)
 
(0)
 
9.7 ± 8.5 (3)
 


OLT patients; n = 51

Non-OLT patients; n = 70

PCT-FFP (no.)
C-FFP (no.)
PCT-FFP (no.)
C-FFP (no.)
Units of study FFP*  21.3 ± 16.1 (22)   22.7 ± 15.8 (29)   7.2 ± 7.9 (38)   9.6 ± 12.9 (32)  
Volume of study FFP, L  4.8 ± 3.7   5.2 ± 3.6   1.6 ± 1.7   2.2 ± 3.0  
Off-study FFP  0.5 ± 1.9 (2)   0.7 ± 2.4 (4)   0.1 ± 0.3 (1)   0.6 ± 2.1 (3)  
Red blood cells§  11.8 ± 6.1 (22)   13.4 ± 10.2 (29)   3.8 ± 2.2 (21)   4.9 ± 4.9 (16)  
Platelets§  13.4 ± 11.3 (18)   16.5 ± 17.3 (24)   7.6 ± 17.0 (16)   6.1 ± 7.2 (9)  
Cryoprecipitate
 
15.8 ± 8.4 (9)
 
13.8 ± 5.2 (8)
 
(0)
 
9.7 ± 8.5 (3)
 

P > .05 for use of all blood components by patient group. The number of patients (n) is indicated by indication and treatment group.

*

Mean number ± SD of study FFP units transfused during the 7-day period of support. Volumes of PCT-FFP and C-FFP units were between 200 and 250 mL

Mean volume (liters) of study plasma transfused during 7-day period of support

Mean number ± SD of off-study FFP units transfused during the 7-day period of support

§

Mean number ± SD of units transfused. Platelet units were conventional adult doses containing at least 3.0 × 1011 platelets in 90% of doses

Mean ± SD units of cryoprecipitate where a unit is the amount prepared from 1 unit of FFP

or Create an Account

Close Modal
Close Modal